Mar 21 |
Insider Buys Additional US$51k In Nuvectis Pharma Stock
|
Mar 15 |
Nuvectis Pharma to Present at the 36th Annual Roth Conference
|
Mar 14 |
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
|
Mar 6 |
Nuvectis Pharma GAAP EPS of -$1.43 beats by $0.16
|
Mar 5 |
Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress
|
Mar 5 |
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
|
Feb 19 |
Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownership
|
Feb 9 |
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
|
Feb 9 |
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
|
Dec 18 |
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
|